<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
